$TEVA

Wed: Teva jumps but TASE continues to lose ground

Globes reports the Tel Aviv Stock Exchange fell on July 29, with the Tel Aviv 35 down 0.99% and Tel Aviv 125 down 0.96%. Teva Pharmaceutical (NYSE: TEVA; TASE: TEVA) rose 10.17% after Q2 results and raised revenue guidance. Other movers included Enlight Renewable Energy, Elbit Systems, and banks such as Bank Leumi and Hapoalim.

Original reporting
Published Jul 29, 2026, 6:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 6:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wed: Teva jumps but TASE continues to lose ground — source image
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

Teva’s raised revenue guidance is the only explicitly described company-specific fundamental driver, making it the primary tradable signal. Other large movers are reported without disclosed catalysts, reducing conviction.

02

Market read

For traders, the actionable edge is Teva’s guidance-driven repricing amid a broadly weaker TASE tape.

03

What to watch

The article does not provide the magnitude or specifics of Teva’s raised guidance, nor does it explain the catalysts for other movers, so follow-through risk is elevated.

Relevance 7/10Novelty 6/10Timing: same-day reaction after Teva’s Q2 results and raised revenue guidance

Background

The piece is a Tel Aviv market wrap with index declines, sector weakness, and a standout Teva earnings and guidance catalyst.

Company-level read

Ticker impact

$TEVABullishMedium confidence
Context

Teva led the Tel Aviv 35 Index, up 10.17%, after reporting Q2 results and raising revenue guidance.

Expected impact

Bullish bias for the next few sessions as traders digest the raised revenue guidance; watch for follow-through vs mean reversion.

Evidence & confidence

The article attributes the 10.17% jump directly to Q2 results and raised revenue guidance, which is a concrete catalyst for repricing.

$NICEBullishLow confidence
Context

Nice rose 5.79% on the day, contributing to the Tel Aviv 35 Index’s strongest movers alongside Teva.

Expected impact

Short-term positive drift is possible, but conviction is limited without a disclosed fundamental driver.

Evidence & confidence

No earnings, guidance, deal, or other primary event is described for Nice in the text.

$ENLTBearishLow confidence
Context

Enlight Renewable Energy fell 4.79%, the biggest decliner on the Tel Aviv 35 Index, during a broadly weaker market.

Expected impact

Near-term downside pressure could persist if selling is momentum-driven, but fundamentals are unclear from this text.

Evidence & confidence

The body lists the percentage move without any specific news catalyst for ENLT.

$ESLTBearishLow confidence
Context

Elbit Systems fell 4.30% on the day, among the notable decliners on the Tel Aviv 35 Index.

Expected impact

Potential for continued volatility, but directional conviction is low without a catalyst.

Evidence & confidence

The text only states the percentage move and does not mention earnings, guidance, contracts, or other events for Elbit.

$NVMIBearishLow confidence
Context

Nova Ltd. dropped 3.91% on the day, listed as one of the notable losers on the Tel Aviv 35 Index.

Expected impact

Watch for follow-through only if broader risk-off persists; company-specific signal is weak.

Evidence & confidence

No discrete NVMI-specific catalyst is provided beyond the decline.

Market effects

Technology index down 2% and banking down 1.5% suggest risk-off pressure, which can amplify dispersion around idiosyncratic earnings/guidance winners like Teva.

Tel Aviv indices broadly lower, implying traders may be reallocating within Israel equities rather than adding net risk.

Limited direct global linkage in the text; the main global read-through is Teva’s guidance affecting sentiment toward pharma earnings season.

Counterpoint

Teva’s +10% move may partially reflect positioning and could mean higher near-term volatility rather than a durable trend if the guidance details are already anticipated.

Key entities

  • Teva Pharmaceutical Industries Ltd.

    Reported Q2 results and raised revenue guidance, driving a +10.17% jump and highest turnover on the Tel Aviv 35 Index.

  • Nice

    Reported as up 5.79% on the day, but no specific catalyst is described in the text.

  • Enlight Renewable Energy

    Reported as down 4.79%, with no catalyst provided in the text.

Related articles

$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

$TEVAMedAI 8/10

Teva Reports Positive Phase 2a Results For TEV-408 In Celiac Disease

Teva Pharmaceutical (TEVA) reported positive Phase 2a trial results for TEV-408, an anti-IL-15 monoclonal antibody, in celiac disease. The study met its primary endpoint, showing significant prevention of gluten-induced intestinal damage. TEV-408 also reduced inflammation and improved patient-reported outcomes. The company plans to present further data and host an investor call. TEVA stock closed at $36.19, up 0.39%, and is up 0.77% in pre-market trading.